ANP (Atrial Natriuretic Peptide) vs GHK-Cu (Copper Peptide)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
ANP (Atrial Natriuretic Peptide)
ANP is a cardiac hormone released by atrial myocytes in response to stretch. It promotes natriuresis, diuresis, and vasodilation, playing key roles in blood pressure and fluid regulation.
Full details →GHK-Cu (Copper Peptide)
GHK-Cu is a naturally occurring copper peptide found in human plasma, saliva, and urine. It plays important roles in wound healing, tissue repair, and has shown anti-aging properties in research.
Full details →Side-by-Side Comparison
| Aspect | ANP (Atrial Natriuretic Peptide) | GHK-Cu (Copper Peptide) |
|---|---|---|
| Dose Range | 25 mcg–100 mcg | 1 mg–2 mg |
| Frequency | 1x daily | 1x daily |
| Cycle Length | 1–4 weeks | 4–8 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | Binds to natriuretic peptide receptors (NPR-A) to activate guanylyl cyclase, producing cGMP. This leads to vasodilation, increased kidney filtration, and inhibition of the renin-angiotensin-aldosterone system. | Attracts immune cells and fibroblasts to wound sites, stimulates collagen and glycosaminoglycan synthesis, promotes angiogenesis, and has antioxidant effects. Modulates gene expression related to tissue repair. |
| Typical Dosage | Clinical use: Carperitide (recombinant ANP) used in Japan for acute heart failure at 0.1mcg/kg/min IV infusion. | Topical: Applied as serum or cream 1-2 times daily. Injectable: 1-2mg daily for research purposes. Microneedling protocols often use 0.5-1%. |
| Administration | Intravenous infusion only for clinical applications. Short half-life (~2 minutes) requires continuous administration. | Most commonly used topically for skin applications. Can be injected subcutaneously for systemic effects. Often combined with microneedling for enhanced skin penetration. |
| Side Effects | Hypotension (dose-limiting), headache, nausea, and potential arrhythmias at high doses. | Topical use is generally well-tolerated. May cause temporary skin irritation or redness in sensitive individuals. Injectable use may cause injection site reactions. |
| Best For |
What They Have in Common
ANP (Atrial Natriuretic Peptide), GHK-Cu (Copper Peptide) are both commonly used for:
Which Has Stronger Evidence?
- Recovery & Healing: GHK-Cu (Copper Peptide) has stronger research support.
| Goal | ANP (Atrial Natriuretic Peptide) | GHK-Cu (Copper Peptide) |
|---|---|---|
| Recovery & Healing | medium | high |
Key Studies
ANP (Atrial Natriuretic Peptide)
- Atrial natriuretic peptide (ANP) modulates stress-induced autophagy in endothelial cells.
Biochimica et biophysica acta. Molecular cell research, 2025
- C-atrial natriuretic peptide (ANP)(4-23) attenuates renal fibrosis in deoxycorticosterone-acetate-salt hypertensive mice.
Experimental cell research, 2023
- Novel ANP (Atrial Natriuretic Peptide)-Based Therapy for Hypertension: The Promising Role of a Disease Mechanism Targeted Approach.
Hypertension (Dallas, Tex. : 1979), 2021
GHK-Cu (Copper Peptide)
- Middle-aged mice treated with GHK-Cu peptide administered intraperitoneally or intranasally show behavioral rescue but divergent hippocampal aging programs.
Research square, 2026
- Glycyl-L-histidyl-L-lysine-Cu2(+) (GHK-Cu) Attenuates CuSO(4) or LPS induced-inflammation in Zebrafish larvae model.
European journal of pharmacology, 2026
- The Regenerative Potential of GHK-Cu in Aesthetic Medicine.
Aesthetic surgery journal, 2026
Ready to Learn More?
Looking for trusted sources?